ArticleAntimicrobial agents and chemotherapy2016
Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04886284 (Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- An Achilles' heel for methicillin-resistantAntimicrobial agents and chemotherapy · 2026Review
- Combination antibiotic therapy in Staphylococcus aureus endocarditis: evidence, controversies, and future directions.Infection · 2026Review
- Article
- ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Successful resolution of methicillin-sensitiveEuropean heart journal. Case reports · 2026Article
- Overcoming Ceftaroline Resistance in MRSA Using Ceftaroline-Carbapenem Combination Therapy.Open forum infectious diseases · 2026Article
- Management of Infective Endocarditis: A Scoping Review.Journal of Brown hospital medicine · 2026Review
- Article
- Ertapenem Combined With Anti-The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Enhanced Killing of Methicillin-Resistant Staphylococcus aureus With Ceftaroline or Vancomycin in Combination With Carbapenems.The Journal of infectious diseases · 2025Article
- Review
- 1-Minute Pearls/Pitfalls for the Clinician.Journal of Brown hospital medicine · 2025Article
- Article
- Anti-virulence and bactericidal activities of Stattic againstApplied and environmental microbiology · 2023Article
- Re-evaluation of FDA-approved antibiotics with increased diagnostic accuracy for assessment of antimicrobial resistance.Cell reports. Medicine · 2023Article
- Treatment of Bacterial Infections with β-Lactams: Cooperation with Innate Immunity.Infection and immunity · 2023Review
- Successful use of nafcillin and ceftaroline combination therapy for persistent MSSA bacteraemia and endocarditis: a case series.JAC-antimicrobial resistance · 2023Article
- AngioVac system guided removal of vegetations from pacemaker lead-related infective endocarditis.BMJ case reports · 2023Article
- Oxacillin plus ertapenem rapidly clears persistent left ventricular assist device-related methicillin-susceptible Staphylococcus aureus bacteremia.Journal of cardiac surgery · 2022Article
- Potent Activity of Ertapenem Plus Cefazolin Within Staphylococcal Biofilms: A Contributing Factor in the Treatment of Methicillin-SusceptibleOpen forum infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Ertapenem and cefazolin were used in combination to successfully clear refractory methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. In addition, recent work has demonstrated activity of combination therapy with beta-lactams from different classes against methicillin-resistant S. aureus (MRSA). The ertapenem-plus-cefazolin combination was evaluated for synergy in vitro and in vivo in a murine skin infection model using an index MSSA bloodstream isolate from a patient in whom persistent bacteremia was cleared with this combination and against a cadre of well-described research strains and clinical strains of MSSA and MRSA. Against the index MSSA bloodstream isolate, ertapenem and cefazolin showed synergy using both checkerboard (fractional inhibitory concentration [FIC] index = 0.375) and time-kill assays. Using a disk diffusion ertapenem potentiation assay, the MSSA isolate showed a cefazolin disk zone increased from 34 to 40 mm. In vitro pharmacokinetic/pharmacodynamic modeling at clinically relevant drug concentrations demonstrated bactericidal activity (>3 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.